R. Jotte

发表

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

K. Nackaerts, M. Socinski, F. Shepherd, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Hung-Ming Wang, R. Greil, K. Harrington, 2019, The Lancet.

An ongoing phase IIIb/IV safety trial of nivolumab (NIVO) in patients (pts) with advanced or metastatic non-small-cell lung cancer (NSCLC) who progressed after receiving 1 or more prior systemic regimens.

H. Burris, D. Spigel, D. Waterhouse, 2015 .

Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.

D. Ettinger, R. Salgia, P. Lorigan, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).

K. Nackaerts, M. Socinski, F. Shepherd, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC

Federico Cappuzzo, M. Socinski, F. Cappuzzo, 2018, The New England journal of medicine.

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

M. Socinski, F. Cappuzzo, T. Mok, 2022, Journal for ImmunoTherapy of Cancer.

IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.

M. Socinski, F. Cappuzzo, D. Moro-Sibilot, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Reovirus-Induced Alterations in Gene Expression Related to Cell Cycle Regulation

R. DeBiasi, K. Tyler, G. Johnson, 2002, Journal of Virology.

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B Unresectable Non-small Cell Lung Cancer

C. Obasaju, S. Feigenberg, B. Movsas, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.

F. Khuri, W. Miller, J. von Pawel, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors

M. Borad, D. V. Von Hoff, G. Weiss, 2012, Clinical Cancer Research.

Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.

Keunchil Park, D. Gandara, J. Infante, 2013 .

Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.

M. Galsky, M. Renschler, R. Jotte, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy.

M. Renschler, R. Jotte, P. Conkling, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma

David A. Smith, D. V. Von Hoff, L. Marton, 2020, Cancer Chemotherapy and Pharmacology.

An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors

David A. Smith, D. V. Von Hoff, F. Braiteh, 2015, Investigational New Drugs.

A phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) that is refractory or progressive within 90 days of completion of first-line platinum-based chemotherapy

D. Ettinger, R. Jotte, J. Oliver, 2008 .

A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy

R. Jotte, C. Reynolds, P. Conkling, 2007 .

Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.

M. Socinski, N. Reinmuth, C. Gridelli, 2020, Clinical lung cancer.

Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).

A. Chiang, L. Hart, M. Pietanza, 2015 .

Myristylation of FBR v-fos dictates the differentiation pathways in malignant osteosarcoma

J. Holt, R. Jotte, 1996, The Journal of cell biology.

Interactions between T helper cells and dendritic cells during the rat mixed lymphocyte reaction

J. Green, R. Jotte, Jon Green aD, 1985, The Journal of experimental medicine.

1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy

C. Blakely, D. Waterhouse, E. Garon, 2021, Annals of Oncology.

nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC

Edward S. Kim, C. Langer, J. Goldman, 2018, Front. Oncol..

Myristylation alters DNA-binding activity and transactivation of FBR (gag-fos) protein

J. Holt, N. Kamata, R. Jotte, 1991, Molecular and cellular biology.

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153

L. Einhorn, D. Spigel, N. Leighl, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.

M. Socinski, F. Cappuzzo, D. Moro-Sibilot, 2018 .

P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153: Topic: IT

E. Stepanski, D. Spigel, D. Waterhouse, 2017 .

Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer

T. Owonikoko, P. Roberts, L. Hart, 2021, Cancer Chemotherapy and Pharmacology.

LBA1_PRPrimary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150)

M. Socinski, D. Moro-Sibilot, F. Barlesi, 2017 .

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.

M. Socinski, F. Cappuzzo, T. Mok, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

C. Obasaju, M. Socinski, R. Govindan, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TRAIL and inhibitors of apoptosis are opposing determinants for NF-κB-dependent, genotoxin-induced apoptosis of cancer cells

K. Tyler, M. Geraci, R. Scheinman, 2002, Oncogene.

Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance

D. Spigel, R. Jotte, 2015, Cancer medicine.

Reovirus-Induced Alteration in Expression of Apoptosis and DNA Repair Genes with Potential Roles in Viral Pathogenesis

R. DeBiasi, K. Tyler, G. Johnson, 2003, Journal of Virology.

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer

J. Neal, H. Wakelee, J. Riess, 2013, British Journal of Cancer.

Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer

C. Obasaju, M. Socinski, D. Patt, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First‐Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)

D. Spigel, D. Waterhouse, E. Garon, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Quality of care of patients with non-small-cell lung cancer: a report of a performance improvement initiative.

F. Hirsch, C. Berry, R. Jotte, 2014, Cancer control : journal of the Moffitt Cancer Center.

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

M. Socinski, F. Cappuzzo, T. Mok, 2019, The Lancet. Respiratory medicine.

Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150.

M. Socinski, F. Cappuzzo, T. Mok, 2021, Journal of Clinical Oncology.

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous Non-Small-Cell Lung Cancer (IMpower131): Results From a Randomized Phase III Trial.

M. Socinski, F. Cappuzzo, V. Graupner, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged ≥70 Years or with Poor Performance Status (CheckMate 153).

L. Einhorn, D. Spigel, N. Leighl, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer

M. Socinski, F. Cappuzzo, T. Mok, 2023, JAMA oncology.

Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.

F. Cappuzzo, Michael Thomas, F. Shepherd, 2017, Lung cancer.

1297ORandomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)

L. Einhorn, D. Spigel, N. Leighl, 2017 .

Results of a phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: An update.

D. Ettinger, P. Lorigan, D. Spigel, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brief Report: Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination with Pegilodecakin in Patients with Metastatic Non-Small-Cell Lung Cancer (CYPRESS-1 and CYPRESS-2).

J. Nemunaitis, D. Ferry, L. Gandhi, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy.

J. Christensen, C. Blakely, P. Olson, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

M. Socinski, F. Cappuzzo, V. Graupner, 2018, Journal of Clinical Oncology.

An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC)

A. Spira, L. Asmar, R. Jotte, 2007 .

Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC)

K. Nackaerts, M. Socinski, F. Shepherd, 2012 .

43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy

D. Waterhouse, E. Garon, A. Spira, 2022, Annals of Oncology.

OA14.02 IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC

M. Socinski, R. Soo, M. Mccleland, 2019, Journal of Thoracic Oncology.

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy

Edward S. Kim, M. Socinski, C. Gridelli, 2017, Lung Cancer.

1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations

M. Socinski, T. Mok, D. Shames, 2020 .

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer

A. Spira, Lina Asmar, L. Asmar, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

IMpower150: Exploratory efficacy analysis in patients (pts) with bulky disease.

J. Subramanian, K. Sabbath, E. Bernicker, 2020 .

IMpower150: Exploratory analysis of brain metastases development.

M. Socinski, F. Cappuzzo, T. Mok, 2020 .

MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Non-Squamous Non-Small Cell Lung Cancer Progressing On/After Checkpoint Inhibitor Therapy or Chemotherapy.

C. Blakely, S. Gadgeel, D. Waterhouse, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations.

M. Socinski, T. Mok, D. Moro-Sibilot, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC.

M. Socinski, V. Graupner, R. Soo, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC).

F. Cappuzzo, F. Shepherd, A. Tsao, 2016 .

Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC).

C. Obasaju, M. Socinski, T. Stinchcombe, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1530PDResults of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)

C. Rudin, A. Chiang, T. Burns, 2017 .

1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations

M. Socinski, T. Mok, F. Barlesi, 2020 .

Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups

M. Socinski, F. Cappuzzo, T. Mok, 2020 .

IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets)

M. Socinski, V. Papadimitrakopoulou, M. Nishio, 2020, Pneumologie.

Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.

D. Ettinger, R. Salgia, P. Lorigan, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

G. Ostoros, R. Jotte, E. Felip, 2023, Annals of Oncology.

ABOUND.70+: Safety and efficacy of nab-paclitaxel/carboplatin (nab-P/C) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC).

Edward S. Kim, C. Langer, J. Goldman, 2017 .

Atezolizumab Treatment of Nonsquamous NSCLC.

M. Socinski, M. Reck, R. Jotte, 2018, The New England journal of medicine.

A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).

J. Neal, H. Wakelee, J. Rigas, 2012 .